Omada Health announced that it will present two abstracts at ObesityWeek 2025 that assess the impact of its digital lifestyle intervention on members currently or previously using GLP-1 medications for weight management. According to the company, the studies examine medication persistence, weight change and program engagement among this population.
In the first analysis, involving 1,124 participants enrolled in Omada’s Enhanced GLP-1 Care Track, the company reported 84% of members remained on therapy for 24 weeks and achieved a 12.1% weight reduction, compared with a 7.4% reduction in those who discontinued. The company said that every additional 10 weekly engagements during the first 12 weeks was associated with a 54% higher likelihood of medication continuation.
The second retrospective analysis reviewed 816 members who ceased GLP-1 treatment and found that 63.2% maintained or further reduced weight at 12 months, with an average gain of 0.8%, notably lower than the 11–12% weight regain seen in prior trial data. According to Omada, these findings suggest its behavioral program may reduce relapse risk after GLP-1 discontinuation.
The company claims that the results support integration of structured lifestyle programs alongside pharmacotherapy to enhance outcomes and lower long-term costs. Omada said the posters will be presented in Atlanta on November 4-5, 2025.
